Mirap (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This combined action boosts noradrenergic and serotonergic activity, contributing to its antidepressant effect.

The appropriate dose of Mirap is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy are limited, and the drug is not recommended unless the potential benefit justifies the risk. It is also excreted in breast milk, so breastfeeding is generally discouraged unless the prescriber decides the benefit outweighs the potential risk to the infant.

To request Mirap, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors, mirtazapine has a distinct receptor profile that often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss. However, its side‑effect profile differs, and choice of therapy should be individualized.

Mirap tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Mirap is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless instructed otherwise.

Serious risks include agranulocytosis, severe hypersensitivity reactions, serotonin syndrome when combined with other serotonergic drugs, and the emergence of suicidal thoughts, especially early in treatment. Patients should be monitored closely for any of these events.

Mirap is contraindicated in patients taking monoamine oxidase inhibitors within 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder or uncontrolled hypertension.